Selective activation of a drug precursor in an orthogonal manner can reduce the adverse systemic effects of the therapy. In a 2015 paper published in Scientific Reports (Vol 5, 9329), HypOxystation users Weiss et al. describe a therapeutic strategy to treat advanced cancers by implanting polymer-entrapped palladium nanoparticles within a tumor in order to continuously induce the activation of propargylated Pro-FUdR to FUdr, a DNA synthesis-disrupting antimetabolite, which is administered enterally. In their paper “Palladium-mediated dealkylation of N-propargyl-floxuridine as a bioorthogonal oxygen-independent prodrug strategy”, they describe the balancing act necessary to design and synthesize a compound that is inactive but resistant to metabolic degradation outside of the tumor, reducing its cytotoxicity for the patient 6,250-fold, which can then be chemically activated by palladium, aided by the specific microenvironment present inside the tumor.
Read more: Treating advanced cancers by implanting polymer-entrapped palladium nano particles within a tumor
Treatment of non-small cell lung cancer NSCLC, the leading cause of cancer-related death, relies heavily on radiation therapy, which however is frequently compromised by development of radioresistance. HypOxystation users Jiang et al. of the University of Oxford describe their study of olaparib, an inhibitor of Poly(ADP-ribose) polymerase 1 (PARP-1) which serves to enhance radiosensitivity, to treat lung carcinoma at hypoxia and normoxia ("Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality"; Int J Radiation Oncol Biol Phys, Vol. 95, No. 2, pp. 772e781, 2016). The lab uses a Don Whitley H35 HypOxystation to create stable, contiguous hypoxic conditions for their cell culture.
A combination of olaparib and radiation significantly increased DNA double strand breaks, and at hypoxia (1% oxygen), the radiation-sensitizing effect of olaparib was increased relative to normoxia (21% oxygen), as evidenced by a decrease in clonogenic survival rates. In vivo effects of oxygen availability were examined in subcutaneous Calu-6 and Calu-3 xenograft assays, where Calu-6 tumors comprise extensive hypoxic areas, and assays focusing on RAD51 protein expression showed that homologous recombination was considerably impacted by olaparib, specifically in hypoxic regions. CC3 staining of Calu-6 tumors as a measure of apoptosis also showed that hypoxic areas are more severely impacted by the combination of olaparib and radiation than normoxic areas. CA9 immunostaining served as a marker for hypoxia.
Read more: Enhancing radiosensitivity to treat lung carcinoma at hypoxia and normoxia